bottom head latest print main concern
lack core earn growth outlook exclud impact
tax reform share buyback thing clearli took turn wors
latest quarter underli profit reflect meaning
declin last year adjust oper incom declin
oper margin decreas bp dont see signific
risk ep guidanc rang despit recent setback less
enthusiast management deliv guidanc magnitud
latest cost cut drive underscor challeng backdrop face
urgenc need address grow headwind
intern retail oper revis price target
base revis estim challeng fundament
revis ep estim
respect factor equiti incom
go forward basi estim
increment weak front-end retail
issu intern retail broad base relat
currenc headwind divestitur boot contract manufactur volum
weak chang loyalti account underli basi
soft intern attribut gener market weak
 overal adj oper incom intern retail
one-third last year meantim retail perform mix
sequenti improv pharmaci trend compar script
y/i howev front-end comp declin
neg impact difficult comparison last year cold/flu season
persist concern need target
promot spend front-end retail exclud retail
gross margin increas bp soft front-end retail
reflect recent larg margin driven promot
strategi cost sale
valuat weve revis price target assum
forward ev/ebitda multipl base histor averag
basi impli price target addit billion
enterpris valu base wba combin ownership
invest use equiti method
risk vulner reimburs pressur currenc risk
gener drug inflat integr risk potenti setback relat
propos merger outcom potenti regulatori
concess addit divestitur market valuat could
jeopard strateg rational acquir divestitur
pivot research group compani
qualiti result rais new concern
unsurprisingli new three-year billion cost cut program announc
latest program come heel major billion cost reduct
initi complet new cost manag program also run parallel
on-go store optim suppos gener million
annual cost save three year grow diverg wba core
oper perform adjust ep expect emphasi go forward
financi engin driven tax rate buyback cost cut without
renew cost cut focu would great difficult bridg gap
adj ep guidanc rang
fifo gross margin gross profit werent materi differ
estim estim compar basi effect tax rate ad
around per share rel assumpt adj oper expens
also bp higher estim
go forward dont expect anniversari fep contract jan result
dramat improv gross margin comparison top chronic reimburs
pressur pharmaci market neg impact shortag
gener
 retail oper appear urgent need margin invest
improv front-end traffic impact tobacco sale weak retail
climat overal cite among retail headwind howev retail gross
margin expand bp exclud impact reflect think
margin driven retail strategi that come expens traffic
still believ manag deliv ep guidanc path
get requir anoth major cost cut program focu new cost
save effort wholesal divis retail oper chile mexico
similar cost associ store optim process also
concern heavi spend requir deliv intend cost save even
one-tim expens exclud pro forma adjust
streamlin wholesal divis exampl cost million deliv
million intend cost save annual
revis price target use forward ev/ebitda multipl
base histor averag impli price target addit
billion enterpris valu base wba combin ownership
invest use equiti method
reimburs pressur one structur impedi gross margin
perform walgreen drug retail peer issu lower
reimburs rate supplier commun reimburs pressur also
contribut earn volatil base specif contractu disput pressur
also repres grow headwind wba european retail oper addit
growth restrict network within payer commun could also neg
implic walgreen oper lastli gener drug inflat could continu
impact financi perform
transact amount spend integr core
financial/oper perform acquir store could dampen effect
exhibit walgreen boot allianc financi summari million except per share data
sale
sell oper
equiti incom affiliates/oth
note earn adjust basi begin
